Environmental Influence on Mental Illness Via Modifications of Genomes and Metabolomes in Adolescents With Autism
NCT ID: NCT06299618
Last Updated: 2024-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
400 participants
OBSERVATIONAL
2024-09-30
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phenotypic and Genetic Factors in Autism Spectrum Disorders
NCT00910559
Autism Biomarker Consortium for Clinical Trials
NCT02996669
Characterisation of Circadian Rhythm in Autistic Spectrum Disorder
NCT01984944
Developing Mental Health Supports for Autistic Students
NCT04926090
An Evaluation of Care (Education) and Treatment Reviews for People With Learning Disabilities and Autistic People
NCT06918483
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. to identify environmental factors which may significantly contribute to the already vulnerable mental health of autistic adolescents in the age group of 11 - 15 years in developing mental illness;
2. to perform quantitative modelling of the Epigenetic - Genetic/Metabolomic - Mental health (EGM) process chain for designing control strategies based on the subjects' personal, environmental, historical, and current state.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be able to interact verbally
* Parental consent and participants must be able and willing to give written informed assent and to comply with the requirements of the study protocol
* Must be willing to return for all study visits and wear the study device at home
* Must have access to and be able to operate a smartphone.
Exclusion Criteria
* Complex medical conditions, which would interfere with ability to take part in the study visits or outcomes.
* Intellectual disability, not capable to attend mainstream school
11 Years
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Southampton
OTHER
Carol Davila University of Medicine and Pharmacy
OTHER
Microlink PC UK LTE
UNKNOWN
Engineering Ingegneria Informatica SpA
UNKNOWN
MEDEA SRL
UNKNOWN
ORTHOKEY ITALIA SRL
UNKNOWN
University College Cork
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Deirdre Murray
Professor Deirdre Murray
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Deirdre Murray, PhD
Role: PRINCIPAL_INVESTIGATOR
University College Cork, Cork, Ireland
Geraldine Boylan, PhD
Role: PRINCIPAL_INVESTIGATOR
University College Cork, Cork, Ireland
Mihai Berteanu, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Medicine and Pharmacy, Bucharest, Romania
Samuele Cortese, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Southampton, Southampton, UK
Koushik Maharatna, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Southampton, Southampton, UK
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University College Cork
Cork, , Ireland
University of Medicine and Pharmacy Carol Davila Bucharest
Bucharest, , Romania
University of Southampton
Southampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Samuele Cortese, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ENIGMA-I
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.